Along with the marked increase of depressive patients, psychiatric terms related to depression have come to be exposed to many lay people in recent years. As a result, various psychiatric terms formerly interpreted and used correctly by psychiatrists have been simplified too much into only a few words such as "utsu", which are often used in an inappropriate way. The new word "utsu" was originally a fragment of words such as "utsu-shoujou" (= depressive symptom),"utsu-joutai" (= depressive state), or "utsu-byou" (= depressive illness). Thus, the lack of postfixes indicating symptom, state, or illness appears to have caused the ambiguity of "utsu". The ambiguity (polysemy) of the word "utsu" is partly derived from that of the English word "depression", which indicates either depressive symptoms or depressive illness, or even within-normal depressed emotion, depending on the context. The use of "utsu-byou" (= depressive illness) is also confusing in terms of which disorders (illnesses) to include, because of the interchangeable use of "utsu" and "utsu-byou". The author contends that the chaotic use of the depression-related terms should be organized along the following "vertical" and "horizontal" axes: the vertical being the symptom-state-illness dimension, and the horizontal being the range of disorders. Specifically, the use of "utsu-byou" should be confined only to depressive illnesses which include definite ICD-10 and DSM-IV disorders, and another term, "yoku-utsu", is recommended for "depressive symptom" and "depressive state" with the postfix of "-shoujou" and "-joutai", respectively. The use of "utsu" in an ambigous way should be avoided. The author also contends that the traditional brief Japanese term "utsu-byou" maintains validity as a term indicating a certain clinical unit in a clinical situation, even though the Japanese translated disorder names of DSM-IV and ICD-10 may also be in use in a formal situation. There are three conditions for the authors' latter contention. First, the conceptual definition of the illness including its longitudinal course should be kept in mind. Secondly, symptom evaluation should be conducted through specialized techniques by psychiatrists. Thirdly, cautious observation looking for new findings should be maintained for a long time in parallel with treatment.
Download full-text PDF |
Source |
---|
Br J Psychiatry
January 2025
Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California Los Angeles, USA; Department of Human Genetics, University of California Los Angeles, USA; and Department of Computational Medicine, University of California Los Angeles, USA.
Background: Accurate diagnosis of bipolar disorder (BPD) is difficult in clinical practice, with an average delay between symptom onset and diagnosis of about 7 years. A depressive episode often precedes the first manic episode, making it difficult to distinguish BPD from unipolar major depressive disorder (MDD).
Aims: We use genome-wide association analyses (GWAS) to identify differential genetic factors and to develop predictors based on polygenic risk scores (PRS) that may aid early differential diagnosis.
BMJ Open
December 2024
Centre for Health Services and Policy Research, The University of British Columbia, Vancouver, British Columbia, Canada.
Objectives: To describe the population that meets the criteria for major depressive disorder (MDD) in British Columbia (BC), compare patterns of healthcare utilisation between those with MDD who are and are not prescribed pharmacotherapy, and assess these relationships in models that control for potential confounding variables.
Design: We used a population cross-sectional study design among a cohort of individuals living with MDD and examined the relationship between pharmacotherapy and healthcare utilisation between 2019 and 2020 using linked billing and administrative data.
Setting: This study identified individuals with MDD using a validated case definition of International Classification of Diseases (ICD) codes in BC, Canada.
J Behav Health Serv Res
January 2025
Transitions to Adulthood Center for Research, Department of Psychiatry, UMass Chan Medical Schoo, 222 Maple Avenue, Shrewsbury, MA, 01545, USA.
This study sought to understand how young adults (age 18-25) with histories of mental health disorders are coping with disrupted transitions to adulthood during the COVID-19 pandemic. A cross-sectional web survey was conducted in March-June 2021 of 967 US young adults with pre-pandemic psychiatric disability to assess their current psychiatric status, interrupted transitions, and associations with social determinants including income, community participation, and social context. Mental health was assessed with the Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder Scale (GAD-7), and PTSD Checklist-Civilian Version.
View Article and Find Full Text PDFBiol Pharm Bull
January 2025
Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan.
Enhanced inflammatory and immune responses have been observed in patients with major depressive disorder, pointing to anti-inflammatory substances as potential seeds for developing novel antidepressants. Omega-3 polyunsaturated fatty acid metabolites, such as resolvin D and E series, maresins, and protectins (collectively known as specialized pro-resolving mediators) demonstrate anti-inflammatory effects. This study examined the antidepressant-like effects of maresin-1 (MaR1) on lipopolysaccharide (LPS)-induced depression-like behaviors in mice.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!